Background <p>Aphthous ulceration is a common disorder of the oral mucosa with a multifactorial etiology, including genetic susceptibility, infections, nutritional deficiencies, hormonal influences, and systemic conditions. Although numerous medications have been reported to induce RAU-like lesions, finasteride—a widely prescribed 5α-reductase inhibitor for male androgenetic alopecia (AGA)—has not previously been implicated.</p> Case presentation <p>A 45-year-old male pharmacist developed RAU-like oral ulcers within one month of initiating finasteride(1&#xa0;mg/day) for AGA at the age of 39. During six years of continuous therapy, painful ulcers recurred two to three times per month despite symptomatic treatments, including vitamin B complex supplementation and topical dexamethasone. Complete resolution occurred after drug discontinuation, followed by prompt recurrence upon supervised rechallenge. Comprehensive investigations excluded nutritional deficiencies, autoimmune diseases, and infectious etiologies. Causality assessment yielded a Naranjo score of 8 (probable), and evaluation using the WHO–UMC system indicated a “certain” causal relationship.</p> Conclusion <p>This case represents the first documented report of finasteride-induced RAU-like lesions, supported by a clear temporal association, a positive dechallenge–rechallenge response, and exclusion of alternative causes. Clinicians should consider finasteride as a potential etiologic factor in patients with refractory or unexplained recurrent oral ulceration.</p>

错误:搜索内容不能为空,请输入英文关键词
错误:关键词超出字数限制,请精简
高级检索

Finasteride-induced recurrent aphthous ulceration–like lesions: a case report with dechallenge–rechallenge confirmation

  • Fukun Li,
  • Chuan Sun,
  • Ye Ye

摘要

Background

Aphthous ulceration is a common disorder of the oral mucosa with a multifactorial etiology, including genetic susceptibility, infections, nutritional deficiencies, hormonal influences, and systemic conditions. Although numerous medications have been reported to induce RAU-like lesions, finasteride—a widely prescribed 5α-reductase inhibitor for male androgenetic alopecia (AGA)—has not previously been implicated.

Case presentation

A 45-year-old male pharmacist developed RAU-like oral ulcers within one month of initiating finasteride(1 mg/day) for AGA at the age of 39. During six years of continuous therapy, painful ulcers recurred two to three times per month despite symptomatic treatments, including vitamin B complex supplementation and topical dexamethasone. Complete resolution occurred after drug discontinuation, followed by prompt recurrence upon supervised rechallenge. Comprehensive investigations excluded nutritional deficiencies, autoimmune diseases, and infectious etiologies. Causality assessment yielded a Naranjo score of 8 (probable), and evaluation using the WHO–UMC system indicated a “certain” causal relationship.

Conclusion

This case represents the first documented report of finasteride-induced RAU-like lesions, supported by a clear temporal association, a positive dechallenge–rechallenge response, and exclusion of alternative causes. Clinicians should consider finasteride as a potential etiologic factor in patients with refractory or unexplained recurrent oral ulceration.